tumor growth and metastasis. Golgi α‐mannosidase II (GMII) has become a therapeutic target for drugs with anticancer activities. One critical task for successful application of GMII drugs in medical treatments is to decrease their unwanted co‐inhibition of lysosomal α‐mannosidase (LMan), a weakness of all known potent GMII inhibitors. A series of novel N‐substituted polyhydroxypyrrolidines was synthesized
抑制高尔基体中复杂 N-聚糖的
生物合成会影响肿瘤生长和转移的进展。高尔基体
α-甘露糖苷酶 II (GMII) 已成为具有抗癌活性的药物的治疗靶点。将 GMII 药物成功应用于医学治疗的一项关键任务是减少它们对溶酶体
α-甘露糖苷酶 (LMan) 的不必要的共抑制,这是所有已知强效 GMII
抑制剂的弱点。合成了一系列新型 N 取代的多羟基
吡咯烷,并用来自黑腹果蝇的模型化 GH38
α-甘露糖苷酶(GMIIb 和 LManII)进行了测试。最有效的结构抑制 GMIIb ( K i =50–76 μ m,由酶测定确定),具有显着的 IC 50选择性指数(LManII)/IC 50 (GMIIb) >100。这些化合物还在癌
细胞系的体外试验中显示出抑制活性(白血病,IC 50 =92–200 μ m),在正常成纤维
细胞系中显示出低细胞毒活性(IC 50 >200 μ m)。此外,它们对 GH47